[
    {
        "question": "How many patients in the dataset have Grade 1 gliomas?",
        "ground_truth": "487 patients have Grade 0 gliomas, and 352 patients have Grade 1 gliomas",
        "derivation": "_.countBy(data, 'Grade')",
        "type": "Information Retrieval",
        "subtype": "Direct Value Retrieval",
        "difficulty": "easy",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There are 352 patients in the dataset with Grade 1 gliomas.",
        "score": 1
    },
    {
        "question": "List the number of patients who have both IDH1 and TP53 mutations (where both values are 1).",
        "ground_truth": "238 patients have both IDH1 and TP53 mutations",
        "derivation": "data.filter(row => row.IDH1 === 1 && row.TP53 === 1).length",
        "type": "Information Retrieval",
        "subtype": "Conditional Retrieval and Filtering",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There are 238 patients who have both IDH1 and TP53 mutations.",
        "score": 1
    },
    {
        "question": "Which genetic mutation (among all recorded mutations) appears most frequently in the dataset?",
        "ground_truth": "IDH1 is the most frequent mutation with 404 cases",
        "derivation": "Object.entries(mutationCounts).sort((a,b) => b[1] - a[1])[0]",
        "type": "Information Retrieval",
        "subtype": "Comparison and Ranking",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The genetic mutation that appears most frequently in the dataset is TP53.",
        "score": 0
    },
    {
        "question": "Group patients by Grade and calculate the average age at diagnosis for each grade.",
        "ground_truth": "Grade 0: 43.87 years, Grade 1: 60.70 years",
        "derivation": "_.groupBy(data, 'Grade').map(group => calculateMean(group.map(p => p.Age_at_diagnosis)))",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The average age at diagnosis for each grade is as follows:\n- Grade 0: 43.87 years\n- Grade 1: 60.70 years",
        "score": 1
    },
    {
        "question": "What is the probability of having an EGFR mutation given that a patient has a Grade 4 glioma?",
        "ground_truth": "31.8% (112 EGFR mutations out of 352 Grade 4 cases)",
        "derivation": "data.filter(row => row.Grade === 4 && row.EGFR === 1).length / data.filter(row => row.Grade === 4).length",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The dataset does not contain any patients with a Grade 4 glioma, so the probability of having an EGFR mutation given a Grade 4 glioma cannot be calculated.",
        "score": 0
    },
    {
        "question": "What is the mean, median, and standard deviation of Age_at_diagnosis in the dataset?",
        "ground_truth": "Mean: 50.94 years, Standard Deviation: 15.69 years",
        "derivation": "const ages = data.map(row => row.Age_at_diagnosis).filter(age => age != null); calculateMean(ages); standardDeviation(ages)",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The mean of `Age_at_diagnosis` is approximately 50.94, the median is 51.55, and the standard deviation is approximately 15.70.",
        "score": 0
    },
    {
        "question": "Is there a noticeable pattern in the co-occurrence of IDH1 and IDH2 mutations across different age groups?",
        "ground_truth": "There are 0 cases of co-occurrence between IDH1 and IDH2 mutations",
        "derivation": "data.filter(row => row.IDH1 === 1 && row.IDH2 === 1).length",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There is no noticeable pattern in the co-occurrence of IDH1 and IDH2 mutations across different age groups, as there are no cases where both mutations occur together in any age group.",
        "score": 1
    },
    {
        "question": "Calculate the variance in age at diagnosis across different glioma grades.",
        "ground_truth": "IDH1-mutated variance: 149.78, IDH1-wildtype variance: 182.16",
        "derivation": "const agesByIdh1 = _.groupBy(data, 'IDH1'); standardDeviation(agesByIdh1[1]) ** 2",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The variance in age at diagnosis for glioma grade 0 is approximately 175.87, and for glioma grade 1, it is approximately 180.29.",
        "score": 0
    },
    {
        "question": "Is there a correlation between EGFR mutation status and glioma grade?",
        "ground_truth": "Grade 0: 6.37% EGFR mutation rate, Grade 1: 23.01% EGFR mutation rate",
        "derivation": "const egfrByGrade = _.groupBy(data, 'Grade'); Object.entries(egfrByGrade).map(([grade, patients]) => ({grade, egfrRate: patients.filter(p => p.EGFR === 1).length / patients.length}))",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There is a weak positive correlation (correlation coefficient of approximately 0.24) between EGFR mutation status and glioma grade.",
        "score": 0
    },
    {
        "question": "Provide a summary of the patient population including grade distribution, gender ratio, and most common mutations.",
        "ground_truth": "Total patients: 839; Grade 0: 487, Grade 1: 352; Males in Grade 0: 271, Females in Grade 0: 216; Males in Grade 1: 217, Females in Grade 1: 135; Most common mutation: IDH1 (404 cases)",
        "derivation": "Multiple analyses combined",
        "type": "Information Retrieval",
        "subtype": "Summary and Reporting",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The patient population consists of 487 patients with Grade 0 and 352 with Grade 1. The gender ratio is 488 males to 351 females. The most common mutations are TP53 (348 occurrences), ATRX (217 occurrences), and PTEN (141 occurrences).",
        "score": 0
    },
    {
        "question": "Calculate the 95% confidence interval for the mean age at diagnosis for patients with IDH1 mutations.",
        "ground_truth": "Mean: 41.67 years, 95% CI: [40.48, 42.87] years",
        "derivation": "confidenceInterval(data.filter(row => row.IDH1 === 1).map(row => row.Age_at_diagnosis))",
        "type": "Statistics",
        "subtype": "Confidence Intervals",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The 95% confidence interval for the mean age at diagnosis for patients with IDH1 mutations is approximately (40.47, 42.87).",
        "score": 0
    },
    {
        "question": "Group patients into clusters based on their mutation profiles (IDH1, TP53, ATRX, PTEN, EGFR) and analyze the characteristics of each cluster.",
        "ground_truth": "Most common patterns: No mutations (170 patients, avg age 59.94), ATRX-IDH1-TP53 (167 patients, avg age 38.41), IDH1 only (146 patients, avg age 46.38)",
        "derivation": "Complex clustering analysis of mutation patterns",
        "type": "Statistics",
        "subtype": "Frequency and Distribution Analysis",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "To group patients into clusters based on their mutation profiles and analyze the characteristics of each cluster, follow these steps in an environment where `scikit-learn` is available:\n\n1. **Install scikit-learn**: Ensure that `scikit-learn` is installed using `pip install scikit-learn`.\n\n2. **Select relevant columns**: Use the mutation profile columns (`IDH1`, `TP53`, `ATRX`, `PTEN`, `EGFR`) for clustering.\n\n3. **Perform K-Means clustering**:\n   ```python\n   from sklearn.cluster import KMeans\n   import pandas as pd\n\n   # Select the relevant columns for clustering\n   mutation_profiles = df[['IDH1', 'TP53', 'ATRX', 'PTEN', 'EGFR']]\n\n   # Perform K-Means clustering\n   kmeans = KMeans(n_clusters=3, random_state=42)\n   df['Cluster'] = kmeans.fit_predict(mutation_profiles)\n   ```\n\n4. **Analyze the characteristics of each cluster**:\n   ```python\n   # Analyze the characteristics of each cluster\n   cluster_analysis = df.groupby('Cluster').mean()\n   print(cluster_analysis)\n   ```\n\nThis will provide the average values of each feature for each cluster, allowing you to analyze the characteristics of each group.",
        "score": 0
    },
    {
        "question": "Analyze the trend of mutation frequencies (IDH1, TP53, ATRX) across different age groups.",
        "ground_truth": "Age <30: IDH1 (82.9%), TP53 (72.4%), ATRX (63.2%); Age 30-45: IDH1 (83.3%), TP53 (59.8%), ATRX (44.3%); Age 45-60: IDH1 (38.0%), TP53 (30.2%), ATRX (15.3%); Age 60+: IDH1 (14.9%), TP53 (26.3%), ATRX (8.0%)",
        "derivation": "Mutation frequencies calculated by age group using groupBy and frequency counts",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The mutation frequencies for IDH1, TP53, and ATRX generally decrease with age, with the highest frequencies observed in younger age groups (0-40 years).",
        "score": 0
    },
    {
        "question": "Based on the mutation data, what might explain the relationship between IDH1 mutation status and patient age at diagnosis?",
        "ground_truth": "IDH1 mutated patients are significantly younger (mean 41.67 years) compared to wild-type (mean ~60 years), with different age distributions and clinical characteristics",
        "derivation": "Analysis of age distributions and confidence intervals by mutation status",
        "type": "Information Retrieval",
        "subtype": "Contextual Interpretation and Explanation",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Patients with the IDH1 mutation are diagnosed at a younger average age (41.67 years) compared to those without the mutation (59.54 years), suggesting an association between IDH1 mutation and younger age at diagnosis.",
        "score": 1
    },
    {
        "question": "What is the relationship between age, gender, and mutation patterns?",
        "ground_truth": "Males and females show different mutation frequencies: Males (Gender=0): IDH1: 46.1%, TP53: 41.4%, ATRX: 23.8%; Females (Gender=1): IDH1: 51.0%, TP53: 41.6%, ATRX: 28.8%",
        "derivation": "Analyzed gender-specific mutation rates using data grouping and frequency calculations",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The analysis shows that younger patients are more likely to have IDH1, ATRX, and TP53 mutations, while older patients may have PTEN and EGFR mutations. Gender does not have a strong linear relationship with age at diagnosis or mutation patterns.",
        "score": 0
    },
    {
        "question": "Analyze the distribution of risk profiles based on mutation combinations.",
        "ground_truth": "Four risk groups identified: Low risk (404 patients, avg age 41.64), High risk (203 patients, avg age 60.89), Mixed (12 patients, avg age 41.39), No risk mutations (220 patients, avg age 59.35)",
        "derivation": "Created risk profiles based on combinations of high-risk (EGFR, PTEN) and low-risk (IDH1, CIC) mutations",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Agent stopped due to iteration limit or time limit.",
        "score": 0
    },
    {
        "question": "What are the racial differences in mutation frequencies, if any?",
        "ground_truth": "Race 0 (n=765): IDH1 49.8%, TP53 42.7%, ATRX 26.3%; Race 1 (n=59): IDH1 25.4%, TP53 30.5%, ATRX 22.0%; Race 2 (n=14): IDH1 57.1%, TP53 21.4%, ATRX 21.4%",
        "derivation": "Calculated mutation rates by racial groups using groupBy and frequency analysis",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The racial differences in mutation frequencies are as follows:\n\n- Race 0 has higher frequencies of mutations in TP53 (42.75%), ATRX (26.27%), and PTEN (16.34%) compared to other races.\n- Race 1 shows notable mutation frequencies in TP53 (30.51%), ATRX (22.03%), and PTEN (25.42%).\n- Race 2 has lower mutation frequencies overall, with TP53 and ATRX both at 21.43%.\n- Race 3 shows no mutations in any of the genes listed.\n\nThese differences indicate that certain mutations are more prevalent in specific racial groups within the dataset.",
        "score": 0
    },
    {
        "question": "Calculate the mutation burden distribution across the dataset.",
        "ground_truth": "Distribution of number of mutations per patient: 0: 124 patients, 1: 213 patients, 2: 262 patients, 3: 201 patients, 4: 35 patients, 5-7: 4 patients",
        "derivation": "Counted total number of mutations per patient and created frequency distribution",
        "type": "Statistics",
        "subtype": "Frequency and Distribution Analysis",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The mutation burden distribution across the dataset is as follows:\n- Count: 839\n- Mean: 1.814\n- Standard Deviation: 1.373\n- Minimum: 0\n- 25th Percentile: 1\n- Median (50th Percentile): 2\n- 75th Percentile: 2\n- Maximum: 17",
        "score": 0
    },
    {
        "question": "What is the relationship between IDH1 mutation and glioma grade?",
        "ground_truth": "In Grade 0 gliomas, 381/487 (78.2%) are IDH1-mutant, while in Grade 1 gliomas, only 23/352 (6.5%) are IDH1-mutant",
        "derivation": "_.groupBy(data, 'Grade'); _.mapValues(groups, g => _.countBy(g, 'IDH1'))",
        "type": "Statistics",
        "subtype": "Frequency and Distribution Analysis",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Gliomas with the IDH1 mutation tend to have a lower grade (mean grade ~0.057) compared to those without the mutation (mean grade ~0.756).",
        "score": 0
    },
    {
        "question": "Is there an age difference between IDH1-mutant and IDH1-wildtype gliomas?",
        "ground_truth": "Yes, IDH1-mutant patients are significantly younger (mean age 41.7 years) compared to IDH1-wildtype patients (mean age 59.5 years)",
        "derivation": "_.groupBy(data, 'IDH1'); calculate mean age for each group",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is an age difference. IDH1-mutant gliomas have a mean age at diagnosis of approximately 41.67 years, while IDH1-wildtype gliomas have a mean age at diagnosis of approximately 59.54 years.",
        "score": 1
    },
    {
        "question": "What is the co-occurrence pattern of IDH1 and TP53 mutations?",
        "ground_truth": "Of IDH1-mutant cases, 238/404 (58.9%) have TP53 mutation. Of IDH1-wildtype cases, only 110/435 (25.3%) have TP53 mutation",
        "derivation": "_.countBy(data, row => `IDH1:${row.IDH1},TP53:${row.TP53}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The co-occurrence pattern shows that IDH1 and TP53 mutations occur together in 238 cases, while IDH1 is mutated without TP53 in 166 cases, and TP53 is mutated without IDH1 in 110 cases.",
        "score": 0
    },
    {
        "question": "What is the distribution of gender in the dataset and how does it relate to mutation status?",
        "ground_truth": "There are 488 females (58.2%) and 351 males (41.8%) in the dataset",
        "derivation": "_.countBy(data, 'Gender')",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "easy",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The dataset has 488 entries for gender '0' and 351 for gender '1'. Both genders show similar mutation patterns, with IDH1, TP53, and ATRX being the most common mutations. Gender '0' has higher mutation counts across most genes.",
        "score": 0
    },
    {
        "question": "What proportion of lower-grade (Grade 0) gliomas have IDH1 mutations?",
        "ground_truth": "Of Grade 0 gliomas, 381/487 (78.2%) have IDH1 mutations",
        "derivation": "filterByGrade(data, 0).filter(row => row.IDH1 === 1).length / filterByGrade(data, 0).length",
        "type": "Information Retrieval",
        "subtype": "Conditional Retrieval and Filtering",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The proportion of lower-grade (Grade 0) gliomas with IDH1 mutations is approximately 78.23%.",
        "score": 1
    },
    {
        "question": "Is there evidence of mutual exclusivity between EGFR and IDH1 mutations?",
        "ground_truth": "Yes, among 112 EGFR-mutant cases, only 4 (3.6%) have IDH1 mutations, suggesting strong mutual exclusivity",
        "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},IDH1:${row.IDH1}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There is no evidence of mutual exclusivity between EGFR and IDH1 mutations, as there are 3 samples with both mutations present.",
        "score": 0
    },
    {
        "question": "Do molecular profiles differ by patient age?",
        "ground_truth": "Yes, IDH1 mutations are significantly more common in younger patients (mean age 41.7 vs 59.5 years), suggesting distinct molecular pathways in different age groups",
        "derivation": "compare mean age between IDH1-mutant and wildtype groups",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, molecular profiles do differ by patient age, as indicated by the varying correlation values between 'Age_at_diagnosis' and the molecular profile columns.",
        "score": 0
    },
    {
        "question": "What is the frequency of ATRX mutations in IDH1-mutant vs IDH1-wildtype gliomas?",
        "ground_truth": "Of the 217 ATRX-mutant cases in the dataset, 189 (87.1%) occur in IDH1-mutant gliomas, showing strong co-occurrence",
        "derivation": "_.countBy(data, row => `ATRX:${row.ATRX},IDH1:${row.IDH1}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The frequency of ATRX mutations in IDH1-mutant gliomas is approximately 46.53%, while in IDH1-wildtype gliomas, it is approximately 6.67%.",
        "score": 0
    },
    {
        "question": "What is the frequency of concurrent mutations in the PI3K pathway (PIK3CA, PIK3R1, PTEN)?",
        "ground_truth": "Only 3 cases (0.36%) show concurrent PIK3CA and PIK3R1 mutations, while 591 cases (70.4%) have no mutations in any of these genes",
        "derivation": "_.countBy(data, row => `PIK3CA:${row.PIK3CA},PIK3R1:${row.PIK3R1},PTEN:${row.PTEN}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The frequency of concurrent mutations in the PI3K pathway (PIK3CA, PIK3R1, PTEN) is 0.",
        "score": 0
    },
    {
        "question": "Is there evidence of mutual exclusivity between PTEN and PIK3CA mutations?",
        "ground_truth": "Yes, of 141 PTEN-mutant cases, only 7 (5%) have concurrent PIK3CA mutations, suggesting mutual exclusivity in the PI3K pathway",
        "derivation": "_.countBy(data.filter(row => row.PTEN === 1), 'PIK3CA')",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "There is no strong evidence of mutual exclusivity between PTEN and PIK3CA mutations, as they occur together in 7 instances.",
        "score": 0
    },
    {
        "question": "How does IDH1 mutation frequency vary across racial groups?",
        "ground_truth": "IDH1 mutation frequencies vary by race: Race 0 (49.8%), Race 1 (25.4%), Race 2 (57.1%), showing significant variation in molecular profiles",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1 mutation frequency varies across racial groups as follows:\n- Race 0: 49.80%\n- Race 1: 25.42%\n- Race 2: 57.14%\n- Race 3: 0.00%",
        "score": 0
    },
    {
        "question": "Is there a difference in EGFR mutation frequency across racial groups?",
        "ground_truth": "EGFR mutation rates vary: Race 0 (12.8%), Race 1 (22.0%), Race 2 (7.1%), suggesting potential racial differences in molecular pathways",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
        "difficulty": "hard",
        "subtype": "Summary and Reporting",
        "type": "Information Retrieval",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is a difference in EGFR mutation frequency across racial groups. The frequencies are as follows: Race 0 has a frequency of 12.81%, Race 1 has a frequency of 22.03%, Race 2 has a frequency of 7.14%, and Race 3 has a frequency of 0%.",
        "score": 0
    },
    {
        "question": "How does IDH1 mutation frequency vary across racial groups?",
        "ground_truth": "IDH1 mutation frequencies vary by race: Race 0 (49.8%), Race 1 (25.4%), Race 2 (57.1%), showing significant variation in molecular profiles",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'IDH1'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1 mutation frequency varies across racial groups as follows:\n- Race 0: 49.80%\n- Race 1: 25.42%\n- Race 2: 57.14%\n- Race 3: 0.00%",
        "score": 0
    },
    {
        "question": "Is there a difference in EGFR mutation frequency across racial groups?",
        "ground_truth": "EGFR mutation rates vary: Race 0 (12.8%), Race 1 (22.0%), Race 2 (7.1%), suggesting potential racial differences in molecular pathways",
        "derivation": "_.mapValues(_.groupBy(data, 'Race'), group => _.countBy(group, 'EGFR'))",
        "type": "Information Retrieval",
        "subtype": "Multi-Column Analysis and Summarization",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Yes, there is a difference in EGFR mutation frequency across racial groups. The frequencies are as follows:\n- Race 0: 12.81%\n- Race 1: 22.03%\n- Race 2: 7.14%\n- Race 3: 0.00%",
        "score": 1
    },
    {
        "question": "What is the pattern of co-occurrence between EGFR and PDGFRA mutations?",
        "ground_truth": "Of 112 EGFR-mutant cases, only 5 (4.5%) have concurrent PDGFRA mutations, while 710 cases (84.6%) have neither mutation",
        "derivation": "_.countBy(data, row => `EGFR:${row.EGFR},PDGFRA:${row.PDGFRA}`)",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "medium",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The pattern of co-occurrence between EGFR and PDGFRA mutations is as follows:\n- Both EGFR and PDGFRA are not mutated in 710 cases.\n- EGFR is not mutated, but PDGFRA is mutated in 17 cases.\n- EGFR is mutated, but PDGFRA is not mutated in 107 cases.\n- Both EGFR and PDGFRA are mutated in 5 cases.",
        "score": 1
    },
    {
        "question": "Are PDGFRA mutations associated with specific molecular subtypes?",
        "ground_truth": "Of 22 PDGFRA-mutant cases, 17 (77.3%) occur in EGFR-wildtype tumors, and 16 (72.7%) in IDH1-wildtype tumors, suggesting a distinct molecular subtype",
        "derivation": "analysis of PDGFRA mutants with EGFR and IDH1 status",
        "type": "Statistics",
        "subtype": "Descriptive Statistics",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "PDGFRA mutations do not show a strong association with specific molecular subtypes based on correlation analysis. The correlations with other molecular subtype columns are generally low.",
        "score": 0
    },
    {
        "question": "Does the IDH1-ATRX-TP53 triple-positive signature represent a distinct biological entity, and what are its clinical implications?",
        "ground_truth": "171 cases (20.4%) show triple-positive signature, with mean age 38.5 years and strong enrichment in Grade 0 (90.1% of triple-positive cases), suggesting a distinct biological subtype with better prognosis",
        "derivation": "Analysis of co-occurrence patterns and clinical features in triple-positive cases",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The IDH1-ATRX-TP53 triple-positive signature is associated with lower-grade tumors and a younger age at diagnosis, suggesting it may represent a distinct biological entity.",
        "score": 0
    },
    {
        "question": "How do alterations in the RTK/PI3K pathway members (EGFR, PDGFRA, PIK3CA, PIK3R1, PTEN) cooperate to drive gliomagenesis, and do they define specific molecular subtypes?",
        "ground_truth": "RTK/PI3K pathway shows distinct patterns: EGFR mutations (13.3%) are mutually exclusive with PDGFRA (2.6%), while PIK3CA/PIK3R1 mutations show limited co-occurrence with PTEN loss, suggesting different mechanisms of pathway activation",
        "derivation": "Complex pathway analysis including mutual exclusivity and co-occurrence patterns",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Agent stopped due to iteration limit or time limit.",
        "score": 0
    },
    {
        "question": "Do the distinct molecular profiles in different age groups suggest different cellular origins or evolutionary paths in glioma development?",
        "ground_truth": "Young patients (<45 years) show enrichment for IDH1-ATRX-TP53 mutations (mean age 38.5), while older patients show EGFR/PTEN alterations (mean age 60.7), suggesting distinct developmental pathways",
        "derivation": "Integration of age patterns with molecular subtypes",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The distribution of molecular features across different age groups has been calculated. This data can be used to analyze potential differences in cellular origins or evolutionary paths in glioma development. The table shows the mean presence of each molecular feature within each age group, which can be further analyzed to draw conclusions.",
        "score": 0
    },
    {
        "question": "How does the interplay between chromatin modifiers (ATRX, SMARCA4, BCOR) and metabolic alterations (IDH1/2) influence glioma development and progression?",
        "ground_truth": "ATRX mutations strongly co-occur with IDH1 (87.1%) but rarely with SMARCA4/BCOR, suggesting distinct chromatin-regulatory mechanisms in IDH-mutant vs wildtype gliomas",
        "derivation": "Analysis of chromatin modifier co-occurrence patterns and associations",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Agent stopped due to iteration limit or time limit.",
        "score": 0
    },
    {
        "question": "How can the distinct molecular subtypes in glioma inform personalized treatment strategies and clinical trial design?",
        "ground_truth": "Four major molecular subtypes identified: IDH-triple (20.4%, mean age 38.5), IDH-only (19.8%, mean age 45.8), RTK/PI3K (24.8%, mean age 60.3), and Other (35%, mean age 54.4). Each shows distinct grade distributions and mutation patterns, suggesting different therapeutic vulnerabilities",
        "derivation": "Integration of molecular subtypes with clinical characteristics",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Agent stopped due to iteration limit or time limit.",
        "score": 0
    },
    {
        "question": "What do the age-specific molecular patterns reveal about glioma biology across different populations, and how should this inform screening and prevention strategies?",
        "ground_truth": "Dramatic shift in molecular profiles with age: IDH-pathway mutations dominate in young patients (<45 years, 83.3%), while RTK/PI3K alterations predominate in older patients (>60 years, 47.2%). This suggests age-specific oncogenic mechanisms requiring different prevention strategies",
        "derivation": "Analysis of age-stratified molecular patterns and risk factors",
        "type": "Information Retrieval",
        "subtype": "Pattern and Trend Recognition",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Age-specific molecular patterns in glioma show that IDH1, TP53, and ATRX mutations are more common in younger patients, while PTEN and EGFR mutations are more prevalent in older individuals. Screening strategies should prioritize these mutations based on age, with potential adjustments for gender and race-specific trends.",
        "score": 0
    },
    {
        "question": "How do the distinct molecular subtypes suggest different evolutionary trajectories in glioma, and what are the implications for treatment resistance?",
        "ground_truth": "Mutation burden analysis shows distinct patterns: IDH-triple subtype has higher mutation burden (mean 3.2 mutations) vs RTK/PI3K subtype (mean 1.8 mutations), suggesting different genomic stability mechanisms and potential resistance pathways",
        "derivation": "Integration of mutation burden, pathway analysis, and clinical correlations",
        "type": "Information Retrieval",
        "subtype": "Data Aggregation, Grouping and Classification",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "The model produced invalid content. Consider modifying your prompt if you are seeing this error persistently.",
        "score": 0
    },
    {
        "question": "How should molecular subtype distributions influence clinical trial design and interpretation in glioma?",
        "ground_truth": "Four distinct molecular subtypes with different ages of onset and clinical features suggest need for subtype-specific trial design: IDH-triple (young, good prognosis), RTK/PI3K (older, poor prognosis), requiring different endpoints and stratification strategies",
        "derivation": "Analysis of subtype-specific characteristics and outcomes",
        "type": "Information Retrieval",
        "subtype": "Summary and Reporting",
        "difficulty": "hard",
        "table_path": "./datasets/research/Glioma.csv",
        "result": "Molecular subtype distributions in glioma, as indicated by genetic markers, should influence clinical trial design and interpretation by enabling patient stratification, guiding targeted therapy development, informing inclusion criteria, aiding in biomarker development, and enhancing the interpretation of trial outcomes. This approach leads to more personalized and effective treatment strategies.",
        "score": 0
    }
]